• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition.未经表皮生长因子受体（EGFR）抑制治疗的EGFR突变型肺腺癌的组织学转化
Lung Cancer. 2017 Mar;105:14-16. doi: 10.1016/j.lungcan.2017.01.005. Epub 2017 Jan 11.
2
Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.表皮生长因子受体突变型肺腺癌中鳞状细胞癌“转化”和 EGFR 外显子 20 S768I 突变的同步发生是一种新的耐药机制。
Lung Cancer. 2017 Jan;103:24-26. doi: 10.1016/j.lungcan.2016.11.012. Epub 2016 Nov 17.
3
Squamous Cell Carcinoma "Transformation" Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas.耐药 EGFR 突变型腺癌中同时发生的鳞状细胞癌“转化”和继发 T790M 突变。
J Thorac Oncol. 2016 Apr;11(4):e49-51. doi: 10.1016/j.jtho.2015.12.096. Epub 2015 Dec 30.
4
EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma.III 期不可手术肺腺癌根治性同步放化疗中 EGFR 突变的影响。
J Thorac Oncol. 2015 Dec;10(12):1720-5. doi: 10.1097/JTO.0000000000000675.
5
The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who recieved concurrent chemoradiotherapy.接受同步放化疗的局部晚期肺腺癌患者中，根据表皮生长因子受体（EGFR）突变状态对临床结局的影响。
Am J Clin Oncol. 2014 Apr;37(2):144-7. doi: 10.1097/COC.0b013e31826e04f9.
6
Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial-mesenchymal transition in a lung adenocarcinoma patient with EGFR-TKI drug resistance.肺腺癌患者 EGFR-TKI 耐药时出现表皮生长因子受体 T790M 继发突变和上皮-间充质转化
Thorac Cancer. 2017 Nov;8(6):693-697. doi: 10.1111/1759-7714.12484. Epub 2017 Aug 8.
7
Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.根据国际肺癌研究协会/美国胸科学会/欧洲呼吸学会新的肺腺癌分类，EGFR突变状态与腺癌主要组织学亚型的相关性。
Arch Pathol Lab Med. 2014 Oct;138(10):1353-7. doi: 10.5858/arpa.2013-0376-OA. Epub 2014 Feb 26.
8
Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.在接受表皮生长因子受体酪氨酸激酶抑制剂治疗的表皮生长因子受体突变型肺腺癌患者中，根据肿瘤负荷和进展模式评估生存结果。
Clin Lung Cancer. 2015 May;16(3):228-36. doi: 10.1016/j.cllc.2014.11.002. Epub 2014 Nov 18.
9
EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust.肺癌患者的表皮生长因子受体（EGFR）突变检测——来自韦斯特福尔医院信托基金的经验
Acta Oncol. 2016;55(2):149-55. doi: 10.3109/0284186X.2015.1062537. Epub 2015 Aug 26.
10
Assessment of prognostic scores of brain metastases from lung adenocarcinoma with EGFR mutations.评估伴有表皮生长因子受体（EGFR）突变的肺腺癌脑转移的预后评分
J Neurooncol. 2017 May;133(1):129-135. doi: 10.1007/s11060-017-2411-2. Epub 2017 Apr 8.

引用本文的文献

1
Histological transformation in lung adenocarcinoma: Insights of mechanisms and therapeutic windows.肺腺癌中的组织学转化：机制与治疗时机的见解
J Transl Int Med. 2024 Nov 6;12(5):452-465. doi: 10.1515/jtim-2024-0019. eCollection 2024 Nov.
2
Evolution and genotypic characteristics of small cell lung cancer transformation in non-small cell lung carcinomas.非小细胞肺癌中小细胞肺癌转化的演变及基因型特征
J Natl Cancer Cent. 2021 Nov 8;1(4):153-162. doi: 10.1016/j.jncc.2021.11.001. eCollection 2021 Dec.
3
Radiomics and deep learning models to differentiate lung adenosquamous carcinoma: A multicenter trial.用于鉴别肺腺鳞癌的影像组学和深度学习模型：一项多中心试验。
iScience. 2023 Aug 16;26(9):107634. doi: 10.1016/j.isci.2023.107634. eCollection 2023 Sep 15.
4
Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report.胃转移和表皮生长因子受体酪氨酸激酶抑制剂获得性耐药后原发性肺腺癌转化为小细胞癌：一例报告。
Medicine (Baltimore). 2021 Oct 1;100(39):e27289. doi: 10.1097/MD.0000000000027289.
5
Case Report: EGFR-Positive Early-Stage Lung Adenocarcinoma Transforming to Squamous Cell Carcinoma After TKI Treatment.病例报告：EGFR 阳性早期肺腺癌在 TKI 治疗后转化为鳞状细胞癌
Front Oncol. 2021 Jun 8;11:696881. doi: 10.3389/fonc.2021.696881. eCollection 2021.
6
[Mechanism of Histologic Transformation of Drive Gene Positive Lung Adenocarcinoma in Targeted Therapy and Treatment Strategy].[驱动基因阳性肺腺癌在靶向治疗中的组织学转化机制及治疗策略]
Zhongguo Fei Ai Za Zhi. 2020 Aug 20;23(8):701-709. doi: 10.3779/j.issn.1009-3419.2020.102.22. Epub 2020 Aug 6.
7
Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma.表皮生长因子受体（EGFR）突变型肺腺癌中的小细胞与鳞状细胞联合转化
Intern Med. 2020 May 15;59(10):1291-1294. doi: 10.2169/internalmedicine.3542-19. Epub 2020 Feb 26.
8
EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE.EBUS-TNBA 22G样本：DAKO与BIOCARE之间程序性死亡受体配体1（PD-L1）表达的比较
J Cancer. 2019 Aug 20;10(20):4739-4746. doi: 10.7150/jca.35898. eCollection 2019.
9
Pathological transition as the arising mechanism for drug resistance in lung cancer.病理性转变作为肺癌耐药产生的机制。
Cancer Commun (Lond). 2019 Oct 1;39(1):53. doi: 10.1186/s40880-019-0402-8.
10
Effect of osimertinib treatment on lung adenocarcinoma with squamous cell transformation harboring the T790M mutation: A case report and literature review.奥希替尼治疗携带T790M突变且发生鳞状细胞转化的肺腺癌的疗效：一例报告及文献综述
Mol Clin Oncol. 2019 Aug;11(2):127-131. doi: 10.3892/mco.2019.1880. Epub 2019 Jun 13.

本文引用的文献

1
Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib.ALK 抑制剂阿来替尼治疗后转化为小细胞肺癌。
J Thorac Oncol. 2016 Jun;11(6):e67-72. doi: 10.1016/j.jtho.2015.12.105. Epub 2016 Jan 2.
2
Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition.腺癌向鳞状细胞癌的组织学转化作为对表皮生长因子受体（EGFR）抑制产生耐药的一种机制。
J Thorac Oncol. 2015 Sep;10(9):e86-e88. doi: 10.1097/JTO.0000000000000571.
3
EGFR-Driven Behavior and Intrapatient T790M Mutation Heterogeneity of Non-Small-Cell Carcinoma With Squamous Histology.表皮生长因子受体驱动的具有鳞状组织学特征的非小细胞肺癌的行为及患者体内T790M突变异质性
J Clin Oncol. 2015 Nov 1;33(31):e115-8. doi: 10.1200/JCO.2013.49.5697. Epub 2014 Apr 21.
4
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.获得性 EGFR 抑制剂耐药的肺癌的基因和组织学演变。
Sci Transl Med. 2011 Mar 23;3(75):75ra26. doi: 10.1126/scitranslmed.3002003.

未经表皮生长因子受体（EGFR）抑制治疗的EGFR突变型肺腺癌的组织学转化

Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition.

作者信息

Le Tri, Sailors Joseph, Oliver Dwight H, Mayer Melissa, Hoskin Sharon, Gerber David E

机构信息

Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States.

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, United States.

出版信息

Lung Cancer. 2017 Mar;105:14-16. doi: 10.1016/j.lungcan.2017.01.005. Epub 2017 Jan 11.

DOI:10.1016/j.lungcan.2017.01.005
PMID:28236979
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5330183/
Abstract

Resistance to EGFR kinase inhibitors appears to be invariable in the treatment of non-small cell lung cancer. Several mechanisms have been described. Here, we report the first case of histologic transformation of EGFR mutant lung adenocarcinoma without prior exposure to EGFR inhibition.

摘要

在非小细胞肺癌的治疗中，对表皮生长因子受体（EGFR）激酶抑制剂的耐药性似乎是不变的。已有多种机制被描述。在此，我们报告首例未经EGFR抑制治疗的EGFR突变型肺腺癌发生组织学转化的病例。